MX2024009492A - Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). - Google Patents
Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).Info
- Publication number
- MX2024009492A MX2024009492A MX2024009492A MX2024009492A MX2024009492A MX 2024009492 A MX2024009492 A MX 2024009492A MX 2024009492 A MX2024009492 A MX 2024009492A MX 2024009492 A MX2024009492 A MX 2024009492A MX 2024009492 A MX2024009492 A MX 2024009492A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- tau181
- treatment
- level
- suspected
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306060P | 2022-02-02 | 2022-02-02 | |
| US202263269394P | 2022-03-15 | 2022-03-15 | |
| US202263364617P | 2022-05-12 | 2022-05-12 | |
| PCT/US2022/079571 WO2023149970A1 (en) | 2022-02-02 | 2022-11-09 | Methods of treatment using p-tau181 level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009492A true MX2024009492A (es) | 2024-08-09 |
Family
ID=84488881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009492A MX2024009492A (es) | 2022-02-02 | 2022-11-09 | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250377367A1 (https=) |
| EP (1) | EP4473009A1 (https=) |
| JP (1) | JP2025506389A (https=) |
| KR (1) | KR20240142535A (https=) |
| AU (1) | AU2022439338A1 (https=) |
| CA (1) | CA3243435A1 (https=) |
| CL (1) | CL2024002309A1 (https=) |
| IL (1) | IL314581A (https=) |
| MX (1) | MX2024009492A (https=) |
| TW (1) | TW202339794A (https=) |
| WO (1) | WO2023149970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025260029A1 (en) * | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
-
2022
- 2022-11-09 AU AU2022439338A patent/AU2022439338A1/en active Pending
- 2022-11-09 CA CA3243435A patent/CA3243435A1/en active Pending
- 2022-11-09 IL IL314581A patent/IL314581A/en unknown
- 2022-11-09 WO PCT/US2022/079571 patent/WO2023149970A1/en not_active Ceased
- 2022-11-09 US US18/835,235 patent/US20250377367A1/en active Pending
- 2022-11-09 MX MX2024009492A patent/MX2024009492A/es unknown
- 2022-11-09 EP EP22822805.2A patent/EP4473009A1/en active Pending
- 2022-11-09 KR KR1020247029332A patent/KR20240142535A/ko active Pending
- 2022-11-09 TW TW111142860A patent/TW202339794A/zh unknown
- 2022-11-09 JP JP2024545951A patent/JP2025506389A/ja active Pending
-
2024
- 2024-07-31 CL CL2024002309A patent/CL2024002309A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024002309A1 (es) | 2025-01-24 |
| KR20240142535A (ko) | 2024-09-30 |
| TW202339794A (zh) | 2023-10-16 |
| CA3243435A1 (en) | 2023-08-10 |
| JP2025506389A (ja) | 2025-03-11 |
| US20250377367A1 (en) | 2025-12-11 |
| AU2022439338A1 (en) | 2024-08-15 |
| WO2023149970A1 (en) | 2023-08-10 |
| IL314581A (en) | 2024-09-01 |
| EP4473009A1 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009492A (es) | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). | |
| MX2025005880A (es) | Metodos de tratamiento que usan un nivel de tomografia de emision de positrones (pet) de tau | |
| WO2020018461A8 (en) | Compositions and methods of diagnosis and treatment for neurological diseases | |
| CL2024000063A1 (es) | Biomarcadores para el tratamiento de la enfermedad de alzheimer | |
| Ding et al. | Cross-modal activation of auditory regions during visuo-spatial working memory in early deafness | |
| Chen et al. | Altered intra‐and interregional synchronization in resting‐state cerebral networks associated with chronic tinnitus | |
| Oh et al. | Beyond dichotomy: patterns and amplitudes of SSEPs and neurological outcomes after cardiac arrest | |
| Ally et al. | Preserved frontal memorial processing for pictures in patients with mild cognitive impairment | |
| ATE419390T1 (de) | Verfahren zur diagnose von bauchspeicheldrüsenkrebs | |
| EP1463531A4 (en) | PROCESS FOR INHIBITING OKULAR PROCESSES | |
| ATE376673T1 (de) | Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten | |
| Michiels et al. | Prognostic indicators for decrease in tinnitus severity after cervical physical therapy in patients with cervicogenic somatic tinnitus | |
| DE602004026767D1 (de) | Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen | |
| WO2022104136A3 (en) | Methods and compositions for tauopathy diagnosis and treatment | |
| Feng et al. | Increased resting-state cerebellar-cerebral functional connectivity underlying chronic tinnitus | |
| CR20230121A (es) | Tratamiento de la enfermedad de parkinson | |
| MX2023006598A (es) | Biomarcadores agonistas del trem2 y métodos para usarlos. | |
| Demopoulos et al. | Global resting‐state functional connectivity of neural oscillations in tinnitus with and without hearing loss | |
| McDermut et al. | Family functioning and suicidality in depressed adults | |
| WO2023129531A3 (en) | Methods for diagnosing and/or treating alzheimer's disease | |
| Giora et al. | Impaired visual processing in patients with insomnia disorder revealed by a dissociation in visual search | |
| Specht et al. | Lexical decision of nonwords and pseudowords in humans: a positron emission tomography study | |
| EA202192176A1 (ru) | Нарушения, опосредованные интерфероном i типа | |
| MX2023014113A (es) | Biomarcadores agonistas de trem2 y métodos para usarlos. | |
| MX2025014802A (es) | Metodos de tratamiento mediante el uso de un anticuerpo anti protofibrillas de peptido beta-amiloide (abeta) |